Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 2
2019 2
2021 2
2022 3
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Results by year

Filters applied: . Clear all
Page 1
Advances in drug treatments for mesothelioma.
Zucali PA, De Vincenzo F, Perrino M, Digiacomo N, Cordua N, D'Antonio F, Borea F, Fazio R, Pirozzi A, Santoro A. Zucali PA, et al. Among authors: digiacomo n. Expert Opin Pharmacother. 2022 Jun;23(8):929-946. doi: 10.1080/14656566.2022.2072211. Epub 2022 May 9. Expert Opin Pharmacother. 2022. PMID: 35508368
Systemic treatments for thymic tumors: a narrative review.
Zucali PA, De Vincenzo F, Perrino M, Digiacomo N, Cordua N, D'Antonio F, Borea F, Santoro A. Zucali PA, et al. Among authors: digiacomo n. Mediastinum. 2021 Sep 25;5:24. doi: 10.21037/med-21-11. eCollection 2021. Mediastinum. 2021. PMID: 35118329 Free PMC article. Review.
Improved outcomes in women with BRAF-mutant melanoma treated with BRAF/MEK-targeted therapy across randomized clinical trials. A systematic review and meta-analysis.
Pala L, De Pas T, Pagan E, Minucci S, Catania C, Digiacomo N, Cocorocchio E, Laszlo D, Di Muzio A, Barigazzi C, Stucchi E, De Grandi L, Stucchi S, Viale G, Gelber RD, Bagnardi V, Conforti F. Pala L, et al. Among authors: digiacomo n. Semin Oncol. 2023 Feb-Apr;50(1-2):34-39. doi: 10.1053/j.seminoncol.2023.03.003. Epub 2023 Mar 21. Semin Oncol. 2023. PMID: 36967333 Review.
Resound Trial: A phase 2 study of regorafenib in patients with thymoma (type B2-B3) and thymic carcinoma previously treated with chemotherapy.
Perrino M, De Pas T, Bozzarelli S, Giordano L, De Vincenzo F, Conforti F, Digiacomo N, Cordua N, D'Antonio F, Borea F, Santoro A, Zucali PA. Perrino M, et al. Among authors: digiacomo n. Cancer. 2022 Feb 15;128(4):719-726. doi: 10.1002/cncr.33990. Epub 2021 Oct 27. Cancer. 2022. PMID: 34706060 Free article. Clinical Trial.
Metronomic combination of Vinorelbine and 5Fluorouracil is able to inhibit triple-negative breast cancer cells. Results from the proof-of-concept VICTOR-0 study.
Cerrito MG, De Giorgi M, Pelizzoni D, Bonomo SM, Digiacomo N, Scagliotti A, Bugarin C, Gaipa G, Grassilli E, Lavitrano M, Giovannoni R, Bidoli P, Cazzaniga ME. Cerrito MG, et al. Among authors: digiacomo n. Oncotarget. 2018 Jun 8;9(44):27448-27459. doi: 10.18632/oncotarget.25422. eCollection 2018 Jun 8. Oncotarget. 2018. PMID: 29937997 Free PMC article.